October 27, 2009 — Women with low- to intermediate-grade ductal carcinoma in situ (DCIS) with margins 3 mm or wider had an "acceptably low rate" of ipsilateral breast events 5 years after excision ...

A newly released study is challenging the way doctors commonly treat patients with ductal carcinoma in situ (DCIS), known as stage zero breast cancer. DCIS cancer cells are confined inside a milk duct ...

There's a long-standing concern among oncologists that many women with ductal carcinoma in situ (DCIS), a potential precursor to invasive breast cancer, receive more treatment than they need. The ...

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, ...

SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended treatment, the randomized COMET ...

Watch and wait may be an alternative to surgery for some women with a very early form of breast cancer. A new study of 957 women evaluated whether it was safe to do active monitoring of a low-risk ...

SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...

DCIS is a pre-invasive breast cancer condition with uncertain progression, often leading to aggressive treatment despite its "stage 0" classification. The lack of definitive guidance for DCIS ...

Please provide your email address to receive an email when new articles are posted on . Patients with DCIS who received tamoxifen had a lower 15-year risk for ipsilateral breast cancer recurrence.

Ductal carcinoma in situ (DCIS) is a non-invasive breast condition found in nearly 20% of breast cancer diagnoses, but a growing number of doctors and medical experts are questioning whether the term ...